MEASLES VIRUS IN CSF:
*Bradstreet et al, presented DAN 2004, not published at that time. 67 children, Group A, 30 with regressive autism after MMR Group B, 37 non autistic having LP [eg leukaemia].
Test for live measles RNA in CSF:
Group A, +ve in 19/28 or 68%
Group B, +ve in 1/37 or 3%
MEASLES VIRUS IN BOWEL:
*Wakefield et al, Lancet 1997; 351: 637-641.
Biopsy of reactive lymphoid follicles and tested for live measles virus RNA
+ve in 81% of ASD patients
+ve in 7% of controls.
J James et al, presented 2004 DAN.
Genetic mutations known as “Single Nucleotide Polymorphisms” for an enzyme important in the methylation pathway [methylenetetrahydrofolate reductase, MTHFR.
+ve in 22% ASD patients
+ve in 11% of controls
J James et al, presented DAN 2004.
Demonstrated significant reduction in levels of methionine, SAMe, cysteine and glutathione in ASD patients cf controls.
Also showed normalization of methionine levels after supplementation with folinic acid, TMG, and MB12 injections.
Three recent studies show reduced antioxidant enzyme activity in ASD group.
This supports the theory that OXIDATIVE STRESS causes autism symptoms in susceptible children.
Thiomerasol [ethyl mercury] has been the preservative of choice in the immunization schedule for many years.
Australia switched to mainly thiomerasol free vaccines in 2001
Assume the allowable mercury exposure is 0.5mcg/day
Assume 2 month 5kgm baby having DTaP, Hep B and HIB on 1 day
Mercury exposure on that day is 62.5mcg [125 times allowable limit]
RELATIVE RISK OF NEURODEVELOPMENT DISORDERS:
|Thiomerasol Vaccine||No Thiomerasol|